Prediction of the renal clearance of cimetidine using endogenous N-1-methylnicotinamide
- PMID: 1826532
- DOI: 10.1007/BF01073868
Prediction of the renal clearance of cimetidine using endogenous N-1-methylnicotinamide
Abstract
We investigated the influence of the type rather than the degree of renal insufficiency on the renal clearance of drugs. Different models of site specific experimental renal failure (ERF) have been developed in the rat; proximal tubular necrosis, induced by cisplatin; papillary necrosis, induced by 2-bromoethylamine, and glomerulonephritis, induced by sodium aurothiomalate or by antiglomerular basement membrane antibody. Several parameters of kidney function were assessed: the clearance of inulin, PAH, and endogenous N-1-methylnicotinamide (NMN). Plasma BUN and creatinine concentrations, and the presence of proteinuria and glucosuria were also measured. Our results showed a nonparallel decrease in glomerular filtration rate (GFR) and tubular secretion as measured by the secretory clearance of endogenous NMN or by the secretory clearance of p-aminohippuric acid (PAH), that is incompatible with the "intact nephron hypothesis." As a result, the renal clearance of cimetidine, a drug eliminated mainly by renal secretion, correlated better with the renal clearance of endogenous NMN than with the GFR. We conclude that (i) our models of ERF demonstrated the existence of glomerulo-tubular imbalance that is contrary to expectations based on the intact nephron hypothesis; (ii) the type of the renal disease has a direct influence on the renal clearance of cimetidine; (iii) the clearance of endogenous NMN may be a valuable noninvasive test for assessing renal tubular secretion which could be useful in predicting the clearance of drugs eliminated predominantly by tubular secretion.
Similar articles
-
Variability in the renal clearance of cephalexin in experimental renal failure.J Pharmacokinet Biopharm. 1993 Feb;21(1):19-30. doi: 10.1007/BF01061773. J Pharmacokinet Biopharm. 1993. PMID: 8410681
-
Estimation of renal secretory function for organic cations by endogenous N1-methylnicotinamide in rats with experimental renal failure.J Pharmacokinet Biopharm. 1984 Feb;12(1):23-42. doi: 10.1007/BF01063609. J Pharmacokinet Biopharm. 1984. PMID: 6235362
-
Renal clearance of N(1)-methylnicotinamide: a sensitive marker of the severity of liver dysfunction in cirrhosis.Nephron. 2000 Jan;84(1):32-9. doi: 10.1159/000045536. Nephron. 2000. PMID: 10644906
-
Proximal Tubular Secretory Clearance: A Neglected Partner of Kidney Function.Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1291-1296. doi: 10.2215/CJN.12001017. Epub 2018 Feb 28. Clin J Am Soc Nephrol. 2018. PMID: 29490976 Free PMC article. Review.
-
How to assess glomerular function and damage in humans.J Hypertens. 1999 Mar;17(3):309-17. doi: 10.1097/00004872-199917030-00002. J Hypertens. 1999. PMID: 10100067 Review.
Cited by
-
The intact nephron hypothesis as a model for renal drug handling.Eur J Clin Pharmacol. 2019 Feb;75(2):147-156. doi: 10.1007/s00228-018-2572-8. Epub 2018 Oct 8. Eur J Clin Pharmacol. 2019. PMID: 30298363
-
Effect of dronedarone on renal function in healthy subjects.Br J Clin Pharmacol. 2007 Dec;64(6):785-91. doi: 10.1111/j.1365-2125.2007.02998.x. Epub 2007 Jul 27. Br J Clin Pharmacol. 2007. PMID: 17662087 Free PMC article. Clinical Trial.
-
Variability in the renal clearance of cephalexin in experimental renal failure.J Pharmacokinet Biopharm. 1993 Feb;21(1):19-30. doi: 10.1007/BF01061773. J Pharmacokinet Biopharm. 1993. PMID: 8410681
-
Impaired Tubular Secretion of Organic Solutes in Acute Kidney Injury.Kidney360. 2020 Aug 27;1(8):724-730. doi: 10.34067/kid.0001632020. Kidney360. 2020. PMID: 35252876 Free PMC article.
-
Renal excretion of apricitabine in rats: ex vivo and in vivo studies.Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):141-50. doi: 10.1007/s13318-011-0038-9. Epub 2011 Apr 6. Eur J Drug Metab Pharmacokinet. 2011. PMID: 21744041
References
MeSH terms
Substances
LinkOut - more resources
Research Materials